Many companies developing artificial intelligence software for healthcare are trying to improve doctors’ ability to diagnose disease. Fewer emerging healthcare AI businesses are focused on what happens after a diagnosis, aiming to figure out how treatments are working.
One of them, AIQ Solutions, has developed software that analyzes medical imaging data to identify all of a cancer patient’s lesions—areas of abnormal tissue—and quantify how they have changed after treatment. CEO Eric Horler claims his company’s technology, focused initially on metastatic bone disease caused by prostate or breast cancer, can provide such insights faster and at a more granular level than competing tools.
“One of the things that’s very difficult for a physician to understand is whether that treatment is really working, and the degree to which it’s working,” Horler says.
Madison, WI-based AIQ received FDA clearance last year to begin marketing its first product, dubbed Quantitative Total Bone Imaging. Now, thanks to an injection of venture capital, the company plans to boost its commercialization efforts and continue developing additional products for various diseases, including bone marrow disorders. Read the full story here.